Skip to main content
. 2016 Mar 2;130:19–26. doi: 10.1016/j.antiviral.2016.03.003

Table 2.

Efficacy of recombinant duck enteritis virus (rDEV) vaccines against the virulent ck/CH/LDL/091022 strain of infectious bronchitis virus (IBV).

Vaccine Dose (pfu) Viral shedding
(%)a
Clinical signs (%)b Survival (Mortality [%]) Seroconversion post-vaccination (%)
Week 1 Week 2 Week 3 Week 4 Week 5
rDEV-N 106 2/10 (20)c 3/10(30)c 7/10 (30) 21/25 (84) 19/25 (76) 10/25 (40) 7/15 (46.7) 7/15 (46.7)
rDEV-S 106 3/10 (30)c 2/10(20)c 9/10 (10) 23/25 (92) 13/25 (52) 4/25 (16) 1/15 (6.7) 1/15 (6.7)
rDEV-S1 106 4/10 (40)c 4/10(40)c 7/10 (30) 23/25 (92) 7/25 (28) 2/25 (8) 2/15 (13.3) 1/15 (6.7)
rDEV-N & rDEV-S 106 2/10 (20)c 2/10(20)c 8/10 (20) 23/25(92) 16/25(64) 13/25(52) 7/15(46.7) 7/15(46.7)
rDEV-N & rDEV-S1 106 2/10 (20)c 2/10(20)c 9/10 (10) 25/25(100) 25/25(100) 21/25(84) 11/15(73.3) 11/15(73.3)
Control 9/10 (90) 8/10(80) 6/10 (40) 0/25 (0) 0/25 (0) 0/25 (0) 0/15 (0) 0/15 (0)
a

Number of chickens shedding IBV on day 5 post-challenge.

b

Clinical signs (%) are presented as the percentage of birds showed clinical signs out of the total number of vaccinated chickens in the group after virulent IBV challenge.

c

p < 0.01, very significant difference, each group was only compared to the control group.